Genomic Risk Evaluation Using Oncotype DX in Young Women (Aged ≤40) With Early-stage, ER-positive, Human Epidermal Growth Factor Receptor 2-negative, and Node-negative Breast Cancer
Journal of Young Women’s Breast Cancer and Health · 2025
DOI: 10.4103/ywbc.ywbc_4_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Young Women’s Breast Cancer and Health, 2025. Verfasst von Rodoniki Iosifidou und 18 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Multigene assays have become a key component in risk stratification of patients with HR+/human epidermal growth factor receptor 2-breast cancer. Among these, the Oncotype DX is a validated tool that predicts the risk of distant recurrence and the potential absolute benefit of adding chemotherapy to adjuvant endocrine therapy. Although breast cancer is less common in younger women, it is often associated with biologically more aggressive features and a worse prognosis. Moreover, this age group has been historically underrepresented in large, randomized clinical trials of Oncotype DX. Hence, younger women are less frequently evaluated with Oncotype DX, and even when testing is performed, the decision to administer chemotherapy is not always aligned with the recurrence score result.
Methods
In this retrospective analysis, a total of 358 young patients were stratified into three genomic risk groups (low, intermediate, and high) according to their Oncotype DX Recurrence Score (RS). A subsequent subgroup analysis focused on identifying individuals within the low genomic risk category who were eligible for treatment with the cyclin-dependent kinase 4 and 6 inhibitor ribociclib.
Results
Among the patients, 41% were classified as low genomic risk, 44% as intermediate, and 15% as high. Notably, 35% of the pT2 patients with low genomic risk were clinically high risk as per the NATALEE trial criteria.
Conclusion
Despite the poorer prognosis in younger women, 41% had a low genomic risk and could potentially be treated effectively with endocrine therapy alone. Among those node-negative patients with tumor size 2–5 cm, one out of three (35%) were classified as clinically high-risk and could benefit from the addition of ribociclib.
Zitieren
APA
Iosifidou, R., Kapetsis, G., Giannoulakis, S., Tsoulos, N., Xepapadakis, G., Markopoulos, C., Papazisis, K., Paraskeva, M., Kaparelou, M., Lainakis, G., Fotarelli, A., Pavlidou, F., Fountzilas, E., Saloustros, E., Karageorgopoulou, S., Triantafillidou, S., Intzes, S., Koinis, F., & Venizelos, V. (2025). Genomic Risk Evaluation Using Oncotype DX in Young Women (Aged ≤40) With Early-stage, ER-positive, Human Epidermal Growth Factor Receptor 2-negative, and Node-negative Breast Cancer. Journal of Young Women’s Breast Cancer and Health. https://doi.org/10.4103/ywbc.ywbc_4_25
Vancouver
Iosifidou R, Kapetsis G, Giannoulakis S, Tsoulos N, Xepapadakis G, Markopoulos C, et al. Genomic Risk Evaluation Using Oncotype DX in Young Women (Aged ≤40) With Early-stage, ER-positive, Human Epidermal Growth Factor Receptor 2-negative, and Node-negative Breast Cancer. Journal of Young Women’s Breast Cancer and Health. 2025. doi:10.4103/ywbc.ywbc_4_25
BibTeX
@article{Iosifidou2025,
author = {Iosifidou, Rodoniki and Kapetsis, George and Giannoulakis, Spiridon and Tsoulos, Nikolaos and Xepapadakis, Grigorios and Markopoulos, Christos and Papazisis, Konstantinos and Paraskeva, Maria and Kaparelou, Maria and Lainakis, Georgios and Fotarelli, Angeliki and Pavlidou, Foteini and Fountzilas, Elena and Saloustros, Emmanouil and Karageorgopoulou, Sofia and Triantafillidou, Sofia and Intzes, Stavros and Koinis, Filippos and Venizelos, Vasileios},
title = {Genomic Risk Evaluation Using Oncotype DX in Young Women (Aged ≤40) With Early-stage, ER-positive, Human Epidermal Growth Factor Receptor 2-negative, and Node-negative Breast Cancer},
journal = {Journal of Young Women’s Breast Cancer and Health},
year = {2025},
doi = {10.4103/ywbc.ywbc_4_25}
}
EUVIMED